Acellular Tissue Engineered Vessel (ATEV)
Phase 3Recruiting 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
End Stage Renal Disease (ESRD)
Conditions
End Stage Renal Disease (ESRD)
Trial Timeline
Sep 7, 2023 → Oct 1, 2027
NCT ID
NCT05908084About Acellular Tissue Engineered Vessel (ATEV)
Acellular Tissue Engineered Vessel (ATEV) is a phase 3 stage product being developed by Humacyte for End Stage Renal Disease (ESRD). The current trial status is recruiting. This product is registered under clinical trial identifier NCT05908084. Target conditions include End Stage Renal Disease (ESRD).
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07141641 | Pre-clinical | Active |
| NCT05908084 | Phase 3 | Recruiting |
Competing Products
20 competing products in End Stage Renal Disease (ESRD)